drug

cosibelimab-ipdl

1 story · latest Nov 6, 2026

Follow cosibelimab-ipdl. Every new filing, FDA action, and trial change, in your feed and a morning email, each linked to its source.

Follow free for 14 daysNo card.

Status: FDA approved Dec 2024 · BLA761297
Brand: Unloxcyt

Relationships

Developed by Checkpoint Therapeutics, Inc

Timeline

FDA approves cosibelimab-ipdl for advanced skin cancer

Nov 6Regulatory decisionCheckpoint Therapeutics, Inc cosibelimab-ipdl

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.